SX-517

SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca2+ flux (IC50=38 nM), and antagonizes CXCL8-induced [ (35) S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model[1][2].

Product Specifications

CAS Number

[1240494-13-6]

UNSPSC

12352005

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sx-517.html

Concentration

10mM

Purity

99.90

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OB(C1=CC=CC=C1CSC2=NC=C(C(NC3=CC=C(F)C=C3)=O)C=C2)O

Molecular Formula

C19H16BFN2O3S

Molecular Weight

382.22

References & Citations

[1]2-[5- (4-Fluorophenylcarbamoyl) pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517) : Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. J Med Chem. 2014 Oct 23;57 (20) :8378-97. |[2]Ti H, et al. Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs) . J Med Chem. 2019 Jul 11;62 (13) :5944-5978.